Related Experiment Video
Updated: Jul 26, 2025
08:11
Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
Published on: November 11, 2022
2.9K
Vonoprazan: A New Potassium-Competitive Acid Blocker
Erin St Onge1, Bradley Phillips1
1Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, FL, USA.
Summary
Vonoprazan, a potassium-competitive acid blocker, shows non-inferior efficacy to proton pump inhibitors for *Helicobacter pylori* eradication. This agent offers a potentially safer and effective alternative for gastrointestinal disorders.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- *Helicobacter pylori* infection is a common cause of gastrointestinal disorders.
- Current treatment guidelines recommend proton pump inhibitors (PPIs) for *H. pylori* eradication.
- Limitations of PPIs include adverse effects, drug interactions, and variable tolerability.
Purpose of the Study:
- To review the safety, efficacy, and tolerability of vonoprazan.
- To evaluate vonoprazan as an alternative acid-suppressing agent for *H. pylori* infection.
Main Methods:
- Literature search of PubMed using keywords: vonoprazan, Voquezna, TAK-438, potassium-competitive acid blocker, *H pylori*, gastrointestinal.
- Inclusion of clinical studies on vonoprazan's pharmacology, pharmacokinetics, efficacy, safety, and tolerability.
Main Results:
- Vonoprazan inhibits gastric acid secretion by competing with potassium on the proton pump.
- Phase 3 trials indicate vonoprazan is non-inferior to PPIs in *H. pylori* eradication regimens.
- Vonoprazan demonstrated efficacy in duodenal ulcer healing and heartburn symptom reduction, with common side effects including nasopharyngitis and diarrhea.
Conclusions:
- Vonoprazan, a potassium-competitive acid blocker (P-CAB), presents a safe and effective alternative to PPIs and H2RAs.
- P-CABs like vonoprazan may offer advantages in managing *H. pylori* infections and other gastrointestinal conditions.
- Further research may support vonoprazan's role in clinical practice for acid-related disorders.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
657
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
657
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
01:20Antiepileptic Drugs: Potassium Channel Activators
218
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
218
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K
01:19Depolarizing Blockers: Pharmocokinetics
353
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
353
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
475
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
475